ACT |
adoptive cell therapy |
ADCs |
antibody-drug conjugated |
AP-1 |
activator protein 1 |
bFGF |
basic fibroblast growth factor |
BsAb |
bispecific monoclonal antibodies |
BCMA |
B-cell maturation antigen |
BsAb |
bispecific antibody |
BiTEs |
bispecific T cell engagers |
BTLA |
band T lymphocyte attenuator |
CAR-NK |
chimeric antigen receptor NK cells |
CAR-T |
chimeric antigen receptor T cells |
CRS |
cytokine release syndrome |
CTLA-4 |
cytotoxic T lymphocyte antigen 4 |
FDA |
food and drug administration |
GvHD |
graft-versus-host disease |
HBV |
hepatitis B virus |
HPV |
human papillomavirus |
HLA |
human leukocyte antigen |
iCasp9 |
inducible Caspase 9 |
ICI |
immune checkpoint inhibitors |
IFN |
interferon |
IL |
interleukin |
iPSC |
induced pluripotent stem cells |
LAG-3 |
lymphocyte activation gene 3 protein |
LPD |
lipid-protamine-DNA |
mAb |
monoclonal antibody |
MDSCs |
myeloid derived suppressor cells |
NF-κB |
nuclear factor kappa B |
mRNA |
messenger RNA |
OTOTT |
on-target-off-tumor-toxicity |
OV |
oncolytic virus |
PD-1 |
programmed cell death protein |
PD-L1 |
programmed cell death protein and its ligand |
scFv |
single chain variable fragment |
STAT3 |
signal transducer and activator of transcription 3 |
TAM |
tumor associated macrophages |
TGF-β |
transforming growth factor beta |
TIL’s |
tumor-infiltrating lymphocytes |
TIM-3 |
T-cell immunoglobulin domain and mucin domain protein 3 |
TME |
tumor microenvironment |
Tregs |
regulatory T cells |
TIGIT |
T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain |
TNF |
tumor necrosis factor |
TRAIL |
TNF related apoptosis inducing ligand |
VEGF |
vascular endothelial growth factor |